Accelerating DoD’s fielding of prototypes for medical countermeasures
The Medical CBRN Defense Consortium (MCDC) is a well-established community of industry, academia, and government focused on rapid prototyping and maturing medical countermeasures to prevent, detect and treat exposure to CBRN threats. Through an Other Transaction Agreement with the JPEO-CBRND (Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense), the MCDC is developing life-saving medical pharmaceutical, diagnostics and therapeutics to safe-guard and enhance the mission effectiveness of our soldiers.
The MCDC scope spans development of medical countermeasure prototypes to include vaccines (COVID-19, Marburg, Ebola, VEE, VEEV, Botulinum, etc.), therapeutics (COVID-19, SNAPP, small molecule antivirals, OPNAs, Smallpox, MDR Bacterial bio threat pathogens, Tularemia, etc.), detection/diagnostics (Meliodiosis, Plague, CRISPR-based, man-portable diagnostics systems, antibody platforms, etc.), autoinjectors (Scopolamine, Naloxone, Diazepam, etc.) and other needs.